Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

BACKGROUND: The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel. METHODS: Patients (n = 507) received...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024054/
https://www.ncbi.nlm.nih.gov/pubmed/25683285
http://dx.doi.org/10.1002/pros.22965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024054/
https://www.ncbi.nlm.nih.gov/pubmed/25683285
http://dx.doi.org/10.1002/pros.22965

Ejemplares similares